Anti-inflammatory pharmaceuticals
|
Commercial opportunity:
Collaboration or licensing opportunity
|
Leiden University has identified
a new adenosine receptor agonist. The innovative
technology that led to its design, synthesis and
pre-clinical evaluations, is now available for
licensing purposes and/or for collaborative
therapeutic development in the area of autoimmune
inflammatory diseases.
Adenosine
receptors (ARs) of which four subtypes exist
(A1, A2A, A2B, A3) are present in the brain, the
heart, the kidneys and the lungs and mediate
diverse physiological functions including
vasodilatation and fluid retention in the
periphery, and cognitive and sleep/wake activity
in the brain. Adenosine receptor ligands have
numerous promising applications and several drug
candidates have been clinically evaluated.
However the ubiquity of adenosine receptors and
the potential side effects impeded the
development of adenosine receptor modulators in
the past, despite their great therapeutic
potential.
Chemists
from Leiden University, the Netherlands, have
synthesized a novel compound proved to be a dual
agonist towards both
A2A
AR and A3 AR. This
compound has high affinity and selectivity for
both human adenosine
A2A
and A3 receptors and
showed to exert strong anti-inflammatory effects
in various pre-clinical animal models of
autoimmune disease.
This new agonist opens
opportunities for new treatment strategies in
conditions of chronic inflammation (arthritis,
colitis, multiple sclerosis) either as
stand-alone application of the compound or in
combination with other drugs.
High
affinity and selectivity for
A2A and A3
adenosine
receptors
Potent anti-inflammatory agent
Treatments for autoimmune inflammatory
diseases such as multiple sclerosis, Crohn’s disease, arthritis.
For this invention a PCT
application has been filed, US, CN, KR, JP patents have
been granted and EP application is still pending.
Wouter van Muijden
Leiden
University
Research & Innovation Services (LURIS)
Poortgebouw Noordvleugel
Rijnsburgerweg 10, 2333 AA Leiden
Tel:
+31(0)71
527 5455
Fax: +31(0)71 527 1764
E-mail:
w.van.muijden@luris.leidenuniv.nl
|
All rights reserved